Novel 3-nitro-1H-1,2,4-triazole-based compounds as potential anti-Chagasic drugs: in vivo studies

Future Medicinal Chemistry

Volumn 5, Issue 15, 2013, Pages 1763-1776

  Papadopoulou, Maria V ^a   Bloomer, William D ^a   Rosenzweig, Howard S ^b   Ashworth, Rachel ^c   Wilkinson, Shane R ^d   Kaiser, Marcel ^e,f   Andriani, Grasiella ^g   Rodriguez, Ana ^g  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b Oakton Community College   (United States)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^f UNIVERSITY OF BASEL   (Switzerland)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITRO 1H 1,2,4 TRIAZOLE DERIVATIVE; AMIDE; ANTIPROTOZOAL AGENT; BENZNIDAZOLE; LUCIFERASE; NITROREDUCTASE; PROPANTHELINE BROMIDE; RANITIDINE; SULFONAMIDE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CHAGAS DISEASE; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; IC 50; IN VITRO STUDY; IN VIVO STUDY; KINETOPLASTIDA; LOW DRUG DOSE; LUMINESCENCE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TRYPANOSOMA CRUZI;

AMIDES; ANIMALS; CACO-2 CELLS; CELL LINE; CELL MEMBRANE PERMEABILITY; CHAGAS DISEASE; EMBRYO, NONMAMMALIAN; HUMANS; ORGANISMS, GENETICALLY MODIFIED; PARASITIC SENSITIVITY TESTS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRIAZOLES; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI; ZEBRAFISH;

EID: 84886532244     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.108     Document Type: Article

References (42)

1. Schmunis GA, Yadon ZE. Chagas disease: A Latin American health problem becoming a world health problem. Acta Trop. 115, 14-21 (2010
2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease (review). Lancet 375(9723), 1388-1402 (2010
3. Leslie M. Infectious diseases. A tropical disease hits the road. Science 333, 934 (2011
4. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N. Engl. J. Med. 364, 2527-2534 (2011
5. Urbina JA. Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches. Acta Trop. 115, 55-68 (2010
6. Urbina JA. Ergosterol biosynthesis and drug development for Chagas disease. Mem. Inst. Oswaldo Cruz 104(Suppl. 1), 311-318 (2009
7. Clayton J. Chagas disease: Pushing through the pipeline. Nature 465, S12-S15 (2010
8. Wilkinson SR, Taylor MC, Horn D et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc. Natl Acad. Sci. USA 105(13), 5022-5027 (2008
9. Alsford S, Eckert S, Baker N et al. High-Throughput decoding of antitrypanosomal drug efficacy and resistance. Nature 482, 232-236 (2010
10. Baker N, Alsford S, Horn D. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6. Mol. Biochem. Parasitol. 176, 55-57 (2011
11. Wilkinson SR, Bot C, Kelly JM et al. Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives. Curr. Top. Med. Chem. 11, 2072-2084 (2011
12. Baliani A, Gerpe A, Aran VJ et al. Design and synthesis of a series of melamine-based nitroheterocycles with activity against trypanosomatid parasites. J. Med. Chem. 48, 5570-5579 (2005
13. Rodriguez J, Aran VJ, Boiani L et al. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: Synthesis, biological evaluation, and mechanism of action studies. Bioorg. Med. Chem. 17, 8186-8196 (2009
14. Boiani L, Gerpe A, Aran VJ et al. In vitro and in vivo antitrypanosomatid activity of 5-nitroindazoles. Eur. J. Med. Chem. 44, 1034-1040 (2009
15. Hall BS, Wu X, Hu L et al. Exploiting the drug-Activating properties of a novel trypanosomal nitroreductase. Antimicrob. Agents Chemother. 54, 1193-1199 (2010
16. Bot C, Hall BS, Bashir N et al. Trypanocidal activity of aziridinyl nitrobenzamide prodrugs. Antimicrob. Agents Chemother. 54(10), 4246-4252 (2010
17. Hu L, Wu X, Han J et al. Synthesis and structure-Activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-Activated prodrugs. Bioorg. Med. Chem. Lett. 21(13), 3986-3991 (2011
18. Papadopoulou MV, Bourdin B, Bloomer W et al. Novel 3-nitro-1,2,4- Triazole-based aliphatic and aromatic amines as anti-Chagasic agents. J. Med. Chem. 54(23), 8214-8223 (2011
19. Papadopoulou MV, Bloomer W, Rosenzweig HS et al. Novel 3-Nitro-1H-1,2,4-Triazole-based amides and sulfonamides as potential anti-Trypanosomal agents. J. Med. Chem. 55(11), 5554-5565 (2012
20. Rosenzweig HS, Papadopoulou MV, Bloomer WD. Interaction of strong DNA-intercalating bioreductive compounds with topoisomerases I and II. Oncol. Res. 15, 219-231 (2005
21. Bustamante JM, Evans A, Papadopoulou MV et al. Use of CD8+ T central memory characteristics as immunologic evidence for treatment efficacy in mice infected with Trypanosoma cruzi. Presented at: 12th Woods Hole Immunoparasitology Meeting. Woods Hole, MA, USA, 27-29 April 2008
22. Canavaci AMC, Bustamante JM, Padilla AM et al. In vitro and in vivo high-Throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl. Trop. Dis. 4(7), e740 (2010
23. Andriani G, Chessler A-DC, Courtemanche G et al. Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl. Trop. Dis. 5(8), e1298 (2011
24. Vazquez MP, Levin MJ. Functional analysis of the intergenic regions of TcP2beta gene loci allowed the construction of an improved Trypanosoma cruzi expression vector. Gene 239, 217-225 (1999
25. Mutlib AE, Dickenson P, Chen S-Y et al. Bioactivation of benzylamine to reactive intermediates in rodents: Formation of glutathione, glutamate, and peptide conjugates. Chem. Res. Toxicol. 15, 1190-1207 (2002
26. Silverman RB, Hawe WP. SAR studies of fluorine-substituted benzylamines and substituted 2-penylethylamines as substrates and inactivators of monoamine oxidase B. J. Enzyme Inhib. 9, 203-215 (1995
27. Stewart BH, Chan OH, Lu RH et al. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models: Relationship to absorption in humans. Pharm. Res. 12, 693 (1995
28. Gozalbes R, Jacewicz M, Annand R et al. QSAR-based permeability model for drug-like compounds. Bioorg. Med. Chem. 19, 2615-2624 (2011
29. Chaturvedi PR, Decker CJ, Odinecs A. Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. Curr. Opin. Chem. Biol. 5, 452-463 (2001
30. Shawahna R, Rahman NU. Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: A provisional biopharmaceutical classification of the list of national essential medicines of Pakistan. DARU 19 (2), 83-99 (2011
31. Maron DM, Ames BN. Revised methods for the Salmonella mutagenicity test. Mutat. Res 113, 173-215 (1983
32. Gee P, Maron DM, Ames BN. Detection and classification of mutagens: A set of base-specific Salmonella tester strains. Proc. Natl Acad. Sci. USA 91, 11606-11610 (1994
33. Ames BN, Gold LS. Chemical carcinogenesis: Too many rodent carcinogens. Proc. Natl Acad. Sci. USA 87(19), 7772-7776 (1990
34. Jenkins GJ, Doak SH, Johnson GE et al. Do dose response thresholds exist for genotoxic alkylating agents? Mutagenesis 20(6), 389-398 (2005
35. Cabrera M, Lavaggi ML, Hernandez P et al. Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5-phenylethenyl-benzofuroxans. Contribution of Phase I metabolites on the mutagenicity induction. Toxicol. Lett. 190, 140-149 (2009
36. Ferreira RC, de Melo ME, Moraes Junior MA et al. Evaluation of genotoxic activity in the blood and urine of guinea pigs treated with nifurtimox and benznidazole. Brazilian J. Med. Biol. Res. 21(5), 1069-1077, 1988
37. Papadopoulou MV, Bloomer WD. Nitroheterocyclic-linked acridines as DNA-Targeting bioreductive agents. Drugs Fut. 18, 231-238 (1993
38. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469 (1994
39. Di L, Kerns EH, Hong Y et al. Development and application of high throughput plasma stability assay for drug discovery. Int. J. Pharm. 297, 110-119 (2005
40. Orhan I, Sener B, Kaiser M et al. Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar. Drugs 8, 47-58 (2010
41. Kimmel CB, Ballard WW, Kimmel SR et al. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253-310 (1995
42. Hotez P, Dumonteil E, Woc-Colburn L et al. Chagas disease: 'the new HIV/AIDS of the Americas.' PLoS Negl. Trop. Dis. 9, e1498 (2012